Lys62

Site Information
TQNVLGEkGRRIREL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3945287

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:	leukemia ( 11 ) , testicular cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 4 , 5 , 6 , 7 , 8 , 9 ) , brain ( 1 ) , F9 (testicular) ( 2 ) , heart ( 1 ) , kidney ( 1 ) , liver ( 1 ) , P19 (testicular) ( 3 ) , pooled tissues ( 1 ) , RAW 264.7 (macrophage) ( 11 ) , thymus ( 10 )

References
1	Wagner SA, et al. (2012) Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 11, 1578-85 22790023 Curated Info
2	Zhou J (2010) CST Curation Set: 9130; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
3	Zhou J (2010) CST Curation Set: 9133; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
4	Tucker M (2010) CST Curation Set: 9089; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
5	Tucker M (2010) CST Curation Set: 9088; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
6	Tucker M (2010) CST Curation Set: 9085; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
7	Tucker M (2010) CST Curation Set: 9087; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
8	Tucker M (2010) CST Curation Set: 9084; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
9	Tucker M (2010) CST Curation Set: 9083; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
10	Guo A (2009) CST Curation Set: 8161; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
11	Possemato A (2009) CST Curation Set: 6916; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/untreated; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info